Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading U.S. medical affairs across asthma and COPD, discusses a recent (Dec 2020) study funded by GSK and co-developed by GSK and CHEST as part of the CHEST “Clinical Perspectives” series evaluating the role of pulmonologists, COPD exacerbations, and the need to improve COPD management and education.
Dr. Riju Ray is an MD/PhD senior medical lead within the Respiratory team at GSK US medical affairs leading teams across both Asthma and COPD. He is based out of Research Triangle Park in North Carolina. Prior to joining GSK Dr. Ray was an assistant professor at the University of Pennsylvania in Philadelphia. Dr. Ray has worked in clinical development leading clinical trials and medical affairs for GSK. He has worked across different therapeutic areas spanning Respiratory disease, Oncology, Neuroscience and Auto-immune diseases.